Steroid Injections After Rhinoplasty: How Kenalog Tames Swelling and Scar

Months after rhinoplasty, some noses stall. The bridge looks finished, but the area just above the tip stays thick and rounded, blurring the definition the surgeon built underneath. For this specific problem, many surgeons reach for a small syringe of triamcinolone acetonide, sold under the brand name Kenalog. It is one of the most useful tools in postoperative care, and one of the least forgiving when overused.

The target is almost always the supratip. The supratip is the soft tissue zone just above the tip, where the skin is thickest and where scar tissue and lymphatic congestion like to collect. When persistent fullness there threatens to form a rounded convexity, sometimes called a pollybeak, a dilute steroid injection can quiet the fibrous buildup and let the underlying cartilage framework show through. The injection works by damping inflammation and slowing the fibroblasts that lay down collagen, essentially telling an overactive scar response to stand down.

Dosing is small, dilute, and spaced out on purpose. Surgeons typically use low concentrations, often in the range of 2.5 to 10 milligrams per milliliter, and inject only a fraction of a milliliter into the deep tissue plane. Injections are usually spaced at least four to six weeks apart, giving each dose time to show its full effect before the next decision. Most patients who need injections at all need somewhere between one and three sessions. More than that is a signal to reassess rather than simply keep injecting.

Thick skinned noses are the classic candidates. Patients with sebaceous, thick nasal skin swell more, hold that swelling longer, and build more scar in the supratip. For them, steroid injections are often discussed before surgery even happens, as part of managing expectations. The broader set of tradeoffs that come with a heavier soft tissue envelope is laid out in thick skin rhinoplasty challenges. Revision patients form the other major group, since operating through old scar provokes more fibrosis, a dynamic explored further in scar tissue in revision rhinoplasty.

The risks are the mirror image of the benefits. The same drug that shrinks scar can shrink healthy tissue. Injected too superficially, too concentrated, or too often, triamcinolone can cause fat and dermal atrophy, leaving a visible depression or a patch of thin, shiny skin. Other described risks include lightening of skin color, visible small vessels, and, rarely, prolonged irregularity that itself needs correction. This is why technique matters as much as the drug: deep placement, conservative volume, and a willingness to wait between doses. A skilled injector treats each session as a question, not a routine.

There is a meaningful list of things injections cannot fix. Steroids act on soft tissue only. They will not lower a cartilage or bony hump, straighten a crooked framework, lift a drooping tip, or correct a structural pollybeak caused by cartilage that was left too high. Injecting a structural problem just thins the skin over it. Distinguishing soft tissue fullness from framework excess is the surgeon's call, usually made by feel, and it determines whether the answer is a syringe, patience, or eventually a revision.

Timing runs alongside the natural swelling curve. Most surgeons will not inject before six to eight weeks, since early swelling resolves on its own and premature steroid exposure risks treating a problem that was already leaving. The tip and supratip are reliably the slowest regions to settle, as covered in tip swelling after rhinoplasty, so restraint in the first months is usually rewarded.

Used with discipline, Kenalog is a quiet success story of rhinoplasty aftercare: a few carefully spaced drops that rescue definition the surgery already created. The skill is knowing when the tissue needs help, and when it just needs time.